Gilead price target raised to $99 from $77 at Leerink Leerink raised its price target for Gilead shares to $99 following the company's better than expected Q4 results and keeps an Outperform rating on the stock.
Bristol-Myers strength attributed to sale chatter The move higher in shares of Bristol-Myers (BMY) is being attributed by traders to chatter of a sale. The stock is up 2%, or $1.06, to $66.08 in morning trading. The unconfirmed talk has the company possibly approaching Gilead (GILD) about buyout interest. Bristol's market capitalization is just above $110B while Gilead's is just above $150B. Shares of Gilead are up 74c to $104.55.